HRP20230381T1 - Pripravci za čišćenje debelog crijeva i liječenje gastrointestinalnih poremećaja - Google Patents
Pripravci za čišćenje debelog crijeva i liječenje gastrointestinalnih poremećaja Download PDFInfo
- Publication number
- HRP20230381T1 HRP20230381T1 HRP20230381TT HRP20230381T HRP20230381T1 HR P20230381 T1 HRP20230381 T1 HR P20230381T1 HR P20230381T T HRP20230381T T HR P20230381TT HR P20230381 T HRP20230381 T HR P20230381T HR P20230381 T1 HRP20230381 T1 HR P20230381T1
- Authority
- HR
- Croatia
- Prior art keywords
- cys
- seq
- glu leu
- tyr
- pro ala
- Prior art date
Links
- 210000001072 colon Anatomy 0.000 title claims 6
- 239000000203 mixture Substances 0.000 title claims 5
- 208000018522 Gastrointestinal disease Diseases 0.000 title 1
- 108010010430 asparagine-proline-alanine Proteins 0.000 claims 62
- KABHAOSDMIYXTR-GUBZILKMSA-N Cys-Glu-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CS)N KABHAOSDMIYXTR-GUBZILKMSA-N 0.000 claims 47
- PLTGTJAZQRGMPP-FXQIFTODSA-N Asn-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(N)=O PLTGTJAZQRGMPP-FXQIFTODSA-N 0.000 claims 46
- ALNKNYKSZPSLBD-ZDLURKLDSA-N Cys-Thr-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O ALNKNYKSZPSLBD-ZDLURKLDSA-N 0.000 claims 33
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 32
- LZMQSTPFYJLVJB-GUBZILKMSA-N Glu-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)N LZMQSTPFYJLVJB-GUBZILKMSA-N 0.000 claims 28
- 108010004073 cysteinylcysteine Proteins 0.000 claims 25
- BOMGEMDZTNZESV-QWRGUYRKSA-N Cys-Tyr-Gly Chemical compound SC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 BOMGEMDZTNZESV-QWRGUYRKSA-N 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 108010061238 threonyl-glycine Proteins 0.000 claims 16
- UQJUGHFKNKGHFQ-VZFHVOOUSA-N Ala-Cys-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UQJUGHFKNKGHFQ-VZFHVOOUSA-N 0.000 claims 14
- CBWCQCANJSGUOH-ZKWXMUAHSA-N Asn-Val-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O CBWCQCANJSGUOH-ZKWXMUAHSA-N 0.000 claims 14
- SBMGKDLRJLYZCU-BIIVOSGPSA-N Cys-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)N)C(=O)O SBMGKDLRJLYZCU-BIIVOSGPSA-N 0.000 claims 13
- NDUSUIGBMZCOIL-ZKWXMUAHSA-N Cys-Asn-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)N NDUSUIGBMZCOIL-ZKWXMUAHSA-N 0.000 claims 12
- YEELWQSXYBJVSV-UWJYBYFXSA-N Ala-Cys-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O YEELWQSXYBJVSV-UWJYBYFXSA-N 0.000 claims 11
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 7
- SNYCNNPOFYBCEK-ZLUOBGJFSA-N Asn-Ser-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O SNYCNNPOFYBCEK-ZLUOBGJFSA-N 0.000 claims 6
- DVKQPQKQDHHFTE-ZLUOBGJFSA-N Cys-Cys-Asn Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)N)C(=O)N DVKQPQKQDHHFTE-ZLUOBGJFSA-N 0.000 claims 6
- 206010036772 Proctalgia Diseases 0.000 claims 6
- WYKJENSCCRJLRC-ZDLURKLDSA-N Thr-Gly-Cys Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N)O WYKJENSCCRJLRC-ZDLURKLDSA-N 0.000 claims 6
- CGDZGRLRXPNCOC-SRVKXCTJSA-N Tyr-Cys-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CGDZGRLRXPNCOC-SRVKXCTJSA-N 0.000 claims 6
- 108010069495 cysteinyltyrosine Proteins 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 6
- OBSIQMZKFXFYLV-QMMMGPOBSA-N L-phenylalanine amide Chemical compound NC(=O)[C@@H](N)CC1=CC=CC=C1 OBSIQMZKFXFYLV-QMMMGPOBSA-N 0.000 claims 5
- 238000002360 preparation method Methods 0.000 claims 5
- -1 C12 alkyl carboxylic acid Chemical class 0.000 claims 4
- BUXAPSQPMALTOY-WHFBIAKZSA-N Cys-Glu Chemical compound SC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O BUXAPSQPMALTOY-WHFBIAKZSA-N 0.000 claims 4
- 206010013554 Diverticulum Diseases 0.000 claims 4
- UYYZZJXUVIZTMH-AVGNSLFASA-N Cys-Glu-Phe Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O UYYZZJXUVIZTMH-AVGNSLFASA-N 0.000 claims 3
- FORGMRSGVSYZQR-YFKPBYRVSA-N L-leucinamide Chemical compound CC(C)C[C@H](N)C(N)=O FORGMRSGVSYZQR-YFKPBYRVSA-N 0.000 claims 3
- KNPVDQMEHSCAGX-UWVGGRQHSA-N Phe-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 KNPVDQMEHSCAGX-UWVGGRQHSA-N 0.000 claims 3
- ALJGSKMBIUEJOB-FXQIFTODSA-N Pro-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@@H]1CCCN1 ALJGSKMBIUEJOB-FXQIFTODSA-N 0.000 claims 3
- LTSIAOZUVISRAQ-QWRGUYRKSA-N Tyr-Gly-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N)O LTSIAOZUVISRAQ-QWRGUYRKSA-N 0.000 claims 3
- WOCYUGQDXPTQPY-FXQIFTODSA-N Val-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](C(C)C)N WOCYUGQDXPTQPY-FXQIFTODSA-N 0.000 claims 3
- 150000001413 amino acids Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 3
- DSLBDPPHINVUID-REOHCLBHSA-N (2s)-2-aminobutanediamide Chemical compound NC(=O)[C@@H](N)CC(N)=O DSLBDPPHINVUID-REOHCLBHSA-N 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- AEJSNWMRPXAKCW-WHFBIAKZSA-N Cys-Ala-Gly Chemical compound SC[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O AEJSNWMRPXAKCW-WHFBIAKZSA-N 0.000 claims 2
- 208000012258 Diverticular disease Diseases 0.000 claims 2
- 206010021518 Impaired gastric emptying Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 2
- GZAUZBUKDXYPEH-CIUDSAMLSA-N Leu-Cys-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)O)N GZAUZBUKDXYPEH-CIUDSAMLSA-N 0.000 claims 2
- WMIOEVKKYIMVKI-DCAQKATOSA-N Leu-Pro-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O WMIOEVKKYIMVKI-DCAQKATOSA-N 0.000 claims 2
- AXDLCFOOGCNDST-UHFFFAOYSA-N N-Methyltyrosine Chemical group CNC(C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-UHFFFAOYSA-N 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- AEEQKUDWJGOFQI-SRVKXCTJSA-N Phe-Cys-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)O)N AEEQKUDWJGOFQI-SRVKXCTJSA-N 0.000 claims 2
- HPYDSVWYXXKHRD-VIFPVBQESA-N Tyr-Gly Chemical compound [O-]C(=O)CNC(=O)[C@@H]([NH3+])CC1=CC=C(O)C=C1 HPYDSVWYXXKHRD-VIFPVBQESA-N 0.000 claims 2
- DBOXBUDEAJVKRE-LSJOCFKGSA-N Val-Asn-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)O)N DBOXBUDEAJVKRE-LSJOCFKGSA-N 0.000 claims 2
- WNNNWFKQCKFSDK-UHFFFAOYSA-N allylglycine Chemical compound OC(=O)C(N)CC=C WNNNWFKQCKFSDK-UHFFFAOYSA-N 0.000 claims 2
- 239000012752 auxiliary agent Substances 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 238000004140 cleaning Methods 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 208000001288 gastroparesis Diseases 0.000 claims 2
- 210000002429 large intestine Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical group C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 claims 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 1
- HCKNAJXCHMACDN-UHFFFAOYSA-N 1-methylpiperidine-4-carboxylic acid Chemical compound CN1CCC(C(O)=O)CC1 HCKNAJXCHMACDN-UHFFFAOYSA-N 0.000 claims 1
- YSFQIJDACSFIOH-UHFFFAOYSA-N 2,2-diaminopropanoic acid Chemical group CC(N)(N)C(O)=O YSFQIJDACSFIOH-UHFFFAOYSA-N 0.000 claims 1
- XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical group OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 claims 1
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- IYCZBJXFSZSHPN-DLOVCJGASA-N Ala-Cys-Phe Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O IYCZBJXFSZSHPN-DLOVCJGASA-N 0.000 claims 1
- OILNWMNBLIHXQK-ZLUOBGJFSA-N Ala-Cys-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O OILNWMNBLIHXQK-ZLUOBGJFSA-N 0.000 claims 1
- 206010002153 Anal fissure Diseases 0.000 claims 1
- PNHQRQTVBRDIEF-CIUDSAMLSA-N Asn-Leu-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)N PNHQRQTVBRDIEF-CIUDSAMLSA-N 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- HRJLVSQKBLZHSR-ZLUOBGJFSA-N Cys-Asn-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O HRJLVSQKBLZHSR-ZLUOBGJFSA-N 0.000 claims 1
- XABFFGOGKOORCG-CIUDSAMLSA-N Cys-Asp-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O XABFFGOGKOORCG-CIUDSAMLSA-N 0.000 claims 1
- YZKOXEJTLWZOQL-GUBZILKMSA-N Cys-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CS)N YZKOXEJTLWZOQL-GUBZILKMSA-N 0.000 claims 1
- HEPLXMBVMCXTBP-QWRGUYRKSA-N Cys-Phe-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O HEPLXMBVMCXTBP-QWRGUYRKSA-N 0.000 claims 1
- GGRDJANMZPGMNS-CIUDSAMLSA-N Cys-Ser-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O GGRDJANMZPGMNS-CIUDSAMLSA-N 0.000 claims 1
- SAEVTQWAYDPXMU-KATARQTJSA-N Cys-Thr-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O SAEVTQWAYDPXMU-KATARQTJSA-N 0.000 claims 1
- YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 claims 1
- 206010011796 Cystitis interstitial Diseases 0.000 claims 1
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- YBAFDPFAUTYYRW-YUMQZZPRSA-N Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O YBAFDPFAUTYYRW-YUMQZZPRSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- MFBYPDKTAJXHNI-VKHMYHEASA-N Gly-Cys Chemical compound [NH3+]CC(=O)N[C@@H](CS)C([O-])=O MFBYPDKTAJXHNI-VKHMYHEASA-N 0.000 claims 1
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 claims 1
- 206010051922 Hereditary non-polyposis colorectal cancer syndrome Diseases 0.000 claims 1
- 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 claims 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 1
- 206010020853 Hypertonic bladder Diseases 0.000 claims 1
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- DKEZVKFLETVJFY-CIUDSAMLSA-N Leu-Cys-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)O)N DKEZVKFLETVJFY-CIUDSAMLSA-N 0.000 claims 1
- 201000005027 Lynch syndrome Diseases 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- 208000030053 Opioid-Induced Constipation Diseases 0.000 claims 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 1
- 208000000450 Pelvic Pain Diseases 0.000 claims 1
- 206010034310 Penile pain Diseases 0.000 claims 1
- MMYUOSCXBJFUNV-QWRGUYRKSA-N Phe-Gly-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N MMYUOSCXBJFUNV-QWRGUYRKSA-N 0.000 claims 1
- 208000037062 Polyps Diseases 0.000 claims 1
- 206010054048 Postoperative ileus Diseases 0.000 claims 1
- 206010036774 Proctitis Diseases 0.000 claims 1
- 206010036783 Proctitis ulcerative Diseases 0.000 claims 1
- 206010036968 Prostatic pain Diseases 0.000 claims 1
- 108010077895 Sarcosine Proteins 0.000 claims 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims 1
- BIYXEUAFGLTAEM-WUJLRWPWSA-N Thr-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(O)=O BIYXEUAFGLTAEM-WUJLRWPWSA-N 0.000 claims 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046477 Urethral syndrome Diseases 0.000 claims 1
- 208000003728 Vulvodynia Diseases 0.000 claims 1
- 206010069055 Vulvovaginal pain Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
- YIYBQIKDCADOSF-UHFFFAOYSA-N alpha-Butylen-alpha-carbonsaeure Natural products CCC=CC(O)=O YIYBQIKDCADOSF-UHFFFAOYSA-N 0.000 claims 1
- 150000001412 amines Chemical group 0.000 claims 1
- 102000016959 beta-3 Adrenergic Receptors Human genes 0.000 claims 1
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 208000013507 chronic prostatitis Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000002052 colonoscopy Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- 229960002591 hydroxyproline Drugs 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 208000020629 overactive bladder Diseases 0.000 claims 1
- 229960001639 penicillamine Drugs 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 229940043230 sarcosine Drugs 0.000 claims 1
- 208000022170 stress incontinence Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 229960004380 tramadol Drugs 0.000 claims 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims 1
- YIYBQIKDCADOSF-ONEGZZNKSA-N trans-pent-2-enoic acid Chemical compound CC\C=C\C(O)=O YIYBQIKDCADOSF-ONEGZZNKSA-N 0.000 claims 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (14)
1. Peptid ili njegova farmaceutski prihvatljiva sol, naznačen time, da peptid sadrži aminokiselinski slijed:
(SEQ ID NO: 2) H-Ag Cys Glu Leu Cys Ag Asn Pro Ala Cys Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 3) C12-BE BK Asn Ser Ser Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 4) C16-BE BK Asn Ser Ser Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 5) C12-BE BK Asn Ser Ser Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr-COOH;
(SEQ ID NO: 6) C14-BE BK Asn Ser Ser Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr-COOH;
(SEQ ID NO: 7) C16-BE BK Asn Ser Ser Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr-COOH;
(SEQ ID NO: 8) H-Cys Ag Glu Leu Cys Cys Asn Pro Ala Ag Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 9) H-Asn Asp Asp Ag Glu Leu Cys Val Asn Val Ala Ag Thr Gly Cys Leu-NH2;
(SEQ ID NO: 10) H-Asn Asp Asp Cys Glu Leu Ag Val Asn Val Ala Cys Thr Gly Ag Leu-NH2;
(SEQ ID NO: 11) C18-BE BK Asn Ser Ser Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr-COOH;
(SEQ ID NO: 12) H-Ag Cys Glu Leu Cys Ag Asn Pro Ala Cys Thr Gly Cys-NH2;
(SEQ ID NO: 13) H-Ag Cys Glu Leu Cys Ag Asn Pro Ala Cys Ala Gly Cys-NH2;
(SEQ ID NO: 14) H-Ag Cys Glu Phe Cys Ag Asn Pro Ala Cys Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 15) H-Ag Cys Glu (4-F)Phe Cys Ag Asn Pro Ala Cys Thr Gly Cys-NH2;
(SEQ ID NO: 16) H-Ag Cys Glu (4-F)Phe Cys Ag Asn Pro Ala Cys Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 17) H-Ag Cys Glu (4-F)Phe Cys Ag Asn Pro Ala Cys Thr Gly Cys (4-F)Phe-NH2;
(SEQ ID NO: 18) H-Cys Cys Glu Leu Ag Cys Asn Pro Ala Cys Thr Gly Ag Tyr-NH2;
(SEQ ID NO: 19) H-Ag Cys Glu Phe Cys Ag Asn Pro Ala Cys Thr Gly Cys-NH2;
(SEQ ID NO: 20) H-Ag Cys Glu Phe Cys Ag Asn Pro Ala Cys Thr Gly Cys (4-F)Phe-NH2;
(SEQ ID NO: 21) H-Cys Cys Glu (4-F)Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 22) H-Cys Cys Glu (4-F)Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys (4-F)Phe-NH2;
(SEQ ID NO: 23) H-Ag Cys Glu Leu Cys Ag Asn Pro Ala Cys Thr Gly Cys (4-F)Phe-NH2;
(SEQ ID NO: 24) H-(4-F)Phe Ag Cys Glu Leu Cys Ag Asn Pro Ala Cys Thr Gly Cys (4-F)Phe-NH2;
(SEQ ID NO: 25) H-Ag Cys Glu Leu Cys Ag Asn Pro Ala Cys Ala Gly Cys Tyr-NH2;
(SEQ ID NO: 26) H-Ag Cys Glu Leu Cys Ag Asn Pro Ala Cys Tyr Gly Cys Tyr-NH2;
(SEQ ID NO: 27) H-Ag Cys Glu Leu Cys Ag Asn Pro Ala Cys Phe Gly Cys Tyr-NH2;
(SEQ ID NO: 28) H-Ag Cys Glu Leu Cys Ag Asn Pro Ala Cys (4-F)Phe Gly Cys Tyr-NH2;
(SEQ ID NO: 29) H-Ag Cys Glu Leu Cys Ag Asn Pro Ala Cys Thr Gly Cys Leu-NH2;
(SEQ ID NO: 30) H-Ag Cys Glu Leu Cys Ag Asn Pro Ala Cys Thr Gly Cys Cha-NH2;
(SEQ ID NO: 31) H-Ag Cys Glu Cha Cys Ag Asn Pro Ala Cys Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 32) H-Ag Cys Glu Leu Cys Ag Asn Pro Ala Cys Thr Gly Cys D-Tyr-NH2;
(SEQ ID NO: 33) H-Ag Pen Glu Leu Cys Ag Asn Pro Ala Pen Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 34) H-Ag Cys Glu Leu Cys Ag Asn Pro Ala Cys Thr Gly Cys Leu Asn-NH2;
(SEQ ID NO: 35) H-Ag Cys Glu Leu Cys Ag Asn Pro Ala Cys Thr Gly Cys Tyr Asn-NH2;
(SEQ ID NO: 36) H-Asp Ag Cys Glu Leu Cys Ag Asn Pro Ala Cys Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 37) H-Ile Asp Ag Cys Glu Leu Cys Ag Asn Pro Ala Cys Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 38) H-Ag Cys Glu Leu Cys Ag Asn OH-Pro Ala Cys Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 39) H-Ag Cys Glu Leu Cys Ag Asn OH-Pro Ala Cys Tyr Gly Cys-NH2;
(SEQ ID NO: 40) H-Ag Cys Glu Leu Pen Ag Asn Pro Ala Cys Thr Gly Pen Tyr-NH2;
(SEQ ID NO: 41) H-Ag Cys Glu Leu Pen Ag Asn Pro Ala Cys Thr Gly Pen Tyr-NH2;
(SEQ ID NO: 42) H-Ag Cys Glu Leu Cys Ag Asn Pro Ala Cys Tyr Gly Cys Nme-Tyr-NH2;
(SEQ ID NO: 43) H-Ag Cys Glu Leu Cys Ag Asn Pro Ala Cys Tyr Gly Cys-COOH;
(SEQ ID NO: 44) H-Ag Cys Glu Leu Cys Ag Asn Pro Ala Cys Cha Gly Cys Tyr-NH2;
(SEQ ID NO: 45) H-Ag Cys Glu Leu Cys Ag Asn Leu Ala Cys Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 46) H-Ag Cys Glu Leu Cys Ag Asn Sar Ala Cys Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 47) H-Ag Cys Glu Leu Cys Ag Asn Val Ala Cys Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 48) H-Ag Cys Glu Leu Cys Ag Asn Pro Ala Cys Tyr Gly Cys Nme-Tyr-NH2;
(SEQ ID NO: 49) H-Ag Cys Glu Leu Cys Ag Leu Pro Ala Cys Tyr Gly Cys-COOH;
(SEQ ID NO: 50) H-Ag Cys Asp Leu Cys Ag Asn Pro Ala Cys Tyr Gly Cys-COOH;
(SEQ ID NO: 51) H-Ag Cys Ser Leu Cys Ag Asn Pro Ala Cys Tyr Gly Cys-COOH;
(SEQ ID NO: 52) H-Ag Cys Thr Leu Cys Ag Asn Pro Ala Cys Tyr Gly Cys-COOH;
(SEQ ID NO: 53) H-Hag Cys Glu Leu Cys Hag Asn Pro Ala Cys Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 54) H-Ag Cys Gln Leu Cys Ag Asn Pro Ala Cys Tyr Gly Cys-COOH;
(SEQ ID NO: 55) H-Ag Cys Glu Leu Cys Ag Leu Pro Ala Cys Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 56) Pent-Cys Glu Leu Cys Ag Asn Pro Ala Cys Tyr Gly Cys Tyr-NH2;
(SEQ ID NO: 57) H-Cys Cys Glu Leu Cys Ag Asn Pro Ala Cys Tyr Gly Ag-COOH;
(SEQ ID NO: 58) Pent-Cys Glu Leu Cys Ag Asn Pro Ala Cys Tyr Gly Cys-COOH;
(SEQ ID NO: 59) H-Hag Cys Glu Leu Cys Hag Asn Pro Ala Cys Tyr Gly Cys-COOH;
(SEQ ID NO: 60) H-Ag Cys Glu Leu Cys Ag Asn Val Ala Cys Tyr Gly Cys Tyr-NH2;
(SEQ ID NO: 61) H-Ag Cys Glu Leu Cys Ag Asn Val Ala Cys Tyr Gly Cys-COOH;
(SEQ ID NO: 62) H-Cys Cth Glu Leu Cys Cys Asn Pro Ala Cys Tyr Gly Cys Tyr-NH2;
(SEQ ID NO: 63) H-Cth Cys Glu Leu Cys Cys Asn Pro Ala Cys Tyr Gly Cys Tyr-NH2;
(SEQ ID NO: 64) H-Cth Cys Glu Leu Cys Cys Asn Pro Ala Cys Tyr Gly Cys-COOH;
(SEQ ID NO: 65) H-Cys Cth Glu Leu Cys Cys Asn Val Ala Cys Tyr Gly Cys Tyr-NH2;
(SEQ ID NO: 66) H-Cys Cth Glu Leu Cys Cys Asn Val Ala Cys Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 67) Ac-Cys Cth Glu Leu Cys Cys Asn Val Ala Cys Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 68) Ac-Cys Cth Glu Leu Cys Cys Asn Pro Ala Cys Tyr Gly Cys Tyr-NH2;
(SEQ ID NO: 69) Ac-Cys Cth Glu Leu Cys Cys Asn Val Ala Cys Tyr Gly Cys-COOH;
(SEQ ID NO: 70) H-Cys Cth Glu Leu Cys Cys Asn Val Ala Cys Tyr Gly Cys-COOH;
(SEQ ID NO: 71) Ac-Cys Cth Glu Leu Cys Cys Asn Pro Ala Cys Tyr Gly Cys-COOH;
(SEQ ID NO: 72) H-Cys Cys Glu Leu Cys Asn Val Ala Cth Tyr Gly Cys-COOH;
(SEQ ID NO: 73) H-Cys Cys Glu Leu Cys Cys Asn Val Ala Cth Tyr Gly Cys Tyr-NH2;
(SEQ ID NO: 74) H-Cys Cys Glu Leu Cys Cth Asn Val Ala Cth Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 75) H-Cys Cys Glu Leu Cys Cth Asn Val Ala Cys Tyr Gly Cys-COOH;
(SEQ ID NO: 76) H-Cys Cys Glu Leu Cys Cth Asn Val Ala Cys Tyr Gly Cys Tyr-NH2;
(SEQ ID NO: 77) H-Cys Cys Glu Leu Cys Cth Asn Val Ala Cys Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 78) 4-Mepip-Cys Cth Glu Leu Cys Cys Asn Val Ala Cys Tyr Gly Cys-COOH;
(SEQ ID NO: 79) H-Cys Cth Glu Leu Cys Cys Asn Val Ala Cys Thr Gly Cys-COOH;
(SEQ ID NO: 80) H-Cys Cth Glu Leu Cys Cys Asn Val Ala Cys Thr Gly Cys-NH2;
(SEQ ID NO: 81) H-Cys Cth Glu Leu Cys Cys Asn Val Ala Cys Phe Gly Cys-COOH;
(SEQ ID NO: 82) H-Ag Ag Glu Leu Ag Ag Asn Pro Ala Ag Thr Gly Ag Tyr-COOH;
(SEQ ID NO: 83) H-Cys Cth Glu Leu Cys Cys Asn Ala Ala Cys Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 84) H-Asp Cys Glu Leu Cys Dpr Asn Val Ala Cys Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 85) H-Cys Cth Glu Leu Cys Cys Asn Val Ala Cys Ser Gly Cys Tyr-NH2;
(SEQ ID NO: 86) H-Cth Glu Leu Cys Ag Asn Val Ala Cys Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 87) H-Ag Cys Glu Leu Cys Ag Asn Val Ala Cys Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 88) H-Ag Cys Glu Leu Cys Ag Asn Pro Ala Cys Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 89) H-Cth Cys Glu Leu Cys Cys Asn Val Ala Cys Thr Gly Cys-COOH;
(SEQ ID NO: 90) H-Cth Cys Glu Leu Cys Cys Asn Val Ala Cys Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 91) H-Cth Cys Glu Leu Cys Cys Asn Val Ala Cys Tyr Gly Cys Tyr-NH2; ili
(SEQ ID NO: 92) H-Cys Cys Glu Leu Cys Cys Asn Val Ala Cth Tyr Gly Cys-COOH;
pri čemu Ag je alilglicin; BE je glutaminska kiselina, gdje bočni lanac karboksilne kiseline formira peptidnu vezu;
BK je lizin, gdje bočni lanac amina formira peptidnu vezu; (4-F)Phe je 4-fluorofenilalanin; Cha je cikloheksilalanin; Pen je penicilamin; OH-Pro je hidroksiprolin; Nme-Tyr je N-metil tirozin; Sar je sarkozin; Hag je alilglicin s reduciranom dikarba vezom; Cth je cistationin; 4-Mepip je 1-metil-piperidin-4-karboksilna kiselina; Dpr je di-aminopropionska kiselina; i pri čemu Ac- označava acetilirani N-završetak; Pent- označava N-završetak pokriven s pentenskom kiselinom; C12- označava N-završetak pokriven sa C12 alkil karboksilnom kiselinom; C14- označava N-završetak pokriven sa C14 alkil karboksilnom kiselinom;
C16- označava N-završetak pokriven sa C16 alkil karboksilnom kiselinom;
C18- označava N-završetak pokriven sa C18 alkil karboksilnom kiselinom;
H- označava nemodificirani N-završetak; -NH2 označava amidirani C-završetak; i
-COOH označava nemodificirani C-završetak.
2. Peptid ili njegova farmaceutski prihvatljiva sol, prema patentnom zahtjevu 1, naznačen time, da peptid sadrži aminokiselinski slijed:
(SEQ ID NO: 2) H-Ag Cys Glu Leu Cys Ag Asn Pro Ala Cys Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 26) H-Ag Cys Glu Leu Cys Ag Asn Pro Ala Cys Tyr Gly Cys Tyr-NH2;
(SEQ ID NO: 43) H-Ag Cys Glu Leu Cys Ag Asn Pro Ala Cys Tyr Gly Cys-COOH;
(SEQ ID NO: 47) H-Ag Cys Glu Leu Cys Ag Asn Val Ala Cys Thr Gly Cys Tyr-NH2;
(SEQ ID NO: 62) H-Ag Cys Glu Leu Cys Ag Asn Val Ala Cys Tyr Gly Cys Tyr-NH2;
(SEQ ID NO: 64) H-Cth Cys Glu Leu Cys Cys Asn Pro Ala Cys Tyr Gly Cys-COOH;
(SEQ ID NO: 68) Ac-Cys Cth Glu Leu Cys Cys Asn Pro Ala Cys Tyr Gly Cys Tyr-NH2;
(SEQ ID NO: 69) Ac-Cys Cth Glu Leu Cys Cys Asn Val Ala Cys Tyr Gly Cys-COOH;
(SEQ ID NO: 70) H-Cys Cth Glu Leu Cys Cys Asn Val Ala Cys Tyr Gly Cys-COOH; ili
(SEQ ID NO: 71) Ac-Cys Cth Glu Leu Cys Cys Asn Pro Ala Cys Tyr Gly Cys-COOH.
3. Peptid ili njegova farmaceutski prihvatljiva sol, prema patentnom zahtjevu 1 ili zahtjevu 2, naznačen time, da se peptid sastoji od jednog od navedenih aminokiselinskih sljedova.
4. Farmaceutski pripravak, naznačen time, da sadrži peptid ili njegovu farmaceutski prihvatljivu sol prema bilo kojem od patentnih zahtjeva 1 do 3, i najmanje jedno farmaceutski prihvatljivo pomoćno sredstvo, razrjeđivač ili nosač.
5. Farmaceutski pripravak prema patentnom zahtjevu 4, naznačen time, da je farmaceutski pripravak čvrsta formulacija za doziranje.
6. Farmaceutski pripravak prema patentnom zahtjevu 5, naznačen time, da je farmaceutski pripravak formuliran kao čvrsta oralna formulacija za doziranje.
7. Pripravak za čišćenje debelog crijeva, naznačen time, da je za uporabu u postupku čišćenja debelog crijeva kod pojedinca, u preparatu za kolonoskopsku proceduru, pri čemu pripravak sadrži farmaceutski prihvatljivo pomoćno sredstvo, razrjeđivač ili nosač, i peptid ili njegovu farmaceutski prihvatljivu sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 3.
8. Pripravak za čišćenje debelog crijeva za uporabu prema patentnom zahtjevu 7, naznačen time, da postupak obuhvaća:
a. oralno ili rektalno davanje pojedincu učinkovite prve doze pripravka za čišćenje debelog crijeva; i
b. davanje pojedincu učinkovite druge doze pripravka za čišćenje debelog crijeva u svrhu temeljitog čišćenja debelog crijeva kod pojedinca.
9. Pripravak za čišćenje debelog crijeva za uporabu prema patentnom zahtjevu 8, naznačen time, da se učinkovita druga doza daje ujutro nakon davanja učinkovite prve doze.
10. Postupak za proizvodnju peptida prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da obuhvaća stvaranje staničnog uzgoja molekule nukleinske kiseline koja kodira peptid, kultiviranje stanice pod uvjetima u kojima se peptid eksprimira, te izoliranje eksprimiranog peptida.
11. Postupak za proizvodnju peptida prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da obuhvaća kemijsko sintetiziranje peptida i pročišćavanje sintetiziranog peptida.
12. Peptid ili njegova farmaceutski prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da je za uporabu u postupku liječenja gastrointestinalnog ili organskog poremećaja kod pojedinca.
13. Peptid ili njegova farmaceutski prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da je za uporabu u postupku liječenja poremećaja kod pojedinca, koji se bira od sljedećih: rak debelog crijeva, hereditarni nepolipozni kolorektalni rak (HNPCC), Lynchov sindrom, gastropareza (GP), polipi, bol, opća abdominalna bol, postoperativni ileus, konstipacija inducirana opoidima, funkcionalna dispepsija, divertikularna bolest uključujući, ali bez ograničenja na SUDD (simptomatska nekomplicirana divertikularna bolest) i SCAD (segmentalni kolitis povezan s divertikulozom), divertikuloza, sindrom iritabilnih crijeva pretežno s proljevom, bol povezana sa sindromom iritabilnih crijeva (IBS), ulcerativni kolitis, ulcerativni proktitis, Crohnova bolest, upalna bolest crijeva (IBD), kronična ili akutna radijacijska protopatija, rektalna bol, kronična proktalgija, proktalgija fugax, analna bol, kronična analna fisura, postoperativna analna bol, sindrom prekomjerne aktivnosti mokraćnog mjehura, stresna inkontinencija, intersticijalni cistitis, sindrom bolova u mokraćnom mjehuru, kolorektalni rak, bol povezana s rakom, opća bol u karlici, endometrioza, orhialgija, kronični prostatitis, prostatodinija, vulvodinija, uretralni sindrom, bol u penisu, perianalna bol i ostali gastrointestinalni i organski poremećaji.
14. Peptid za uporabu prema patentnom zahtjevu 13, naznačen time, da postupak nadalje obuhvaća davanje pojedincu farmaceutskog pripravka koji sadrži djelatni sastojak odabran od opoida, tramadola, agonista beta-3 adrenergijskog receptora, anti-holinergijskih sredstava, i tricikličkih antidepresiva.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562156077P | 2015-05-01 | 2015-05-01 | |
EP16721609.2A EP3288578B8 (en) | 2015-05-01 | 2016-04-29 | Compositions for colon cleansing and the treatment of gastrointestinal disorders |
PCT/US2016/030061 WO2016178979A1 (en) | 2015-05-01 | 2016-04-29 | Compositions for colon cleansing and the treatment of gastrointestinal disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20230381T1 true HRP20230381T1 (hr) | 2023-07-07 |
Family
ID=55953439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20230381TT HRP20230381T1 (hr) | 2015-05-01 | 2016-04-29 | Pripravci za čišćenje debelog crijeva i liječenje gastrointestinalnih poremećaja |
Country Status (23)
Country | Link |
---|---|
US (1) | US10618938B2 (hr) |
EP (2) | EP3288578B8 (hr) |
JP (4) | JP6930919B2 (hr) |
KR (1) | KR20180005675A (hr) |
CN (2) | CN114716514A (hr) |
BR (1) | BR112017023539A2 (hr) |
CA (2) | CA3172777A1 (hr) |
CY (1) | CY1126031T1 (hr) |
DK (1) | DK3288578T3 (hr) |
EA (1) | EA201792401A1 (hr) |
ES (1) | ES2947591T3 (hr) |
FI (1) | FI3288578T3 (hr) |
HR (1) | HRP20230381T1 (hr) |
HU (1) | HUE061954T2 (hr) |
LT (1) | LT3288578T (hr) |
MA (1) | MA41985B1 (hr) |
MD (1) | MD3288578T2 (hr) |
MX (2) | MX2017013928A (hr) |
PL (1) | PL3288578T3 (hr) |
PT (1) | PT3288578T (hr) |
RS (1) | RS64160B1 (hr) |
SI (1) | SI3288578T1 (hr) |
WO (1) | WO2016178979A1 (hr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3464336T3 (pl) | 2016-06-01 | 2022-05-16 | Athira Pharma, Inc. | Związki |
AU2022397387A1 (en) * | 2021-11-24 | 2024-05-30 | Ironwood Pharmaceuticals, Inc. | Synthetic process for production of modified gcc receptor agonists |
WO2023097207A1 (en) * | 2021-11-24 | 2023-06-01 | Ironwood Pharmaceuticals, Inc. | Synthetic process for production of modified gcc receptor agonists |
CA3238619A1 (en) * | 2021-11-29 | 2023-06-01 | Michael Gerber | Pharmaceutical compositions for the treatment of visceral pain |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH689139A5 (de) | 1995-04-03 | 1998-10-30 | Cerbios Pharma Sa | Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung. |
US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
BR122018074353B8 (pt) * | 2003-01-28 | 2023-05-02 | Ironwood Pharmaceuticals Inc | composição farmacêutica, polipeptídeo e métodos para a produção dos mesmos |
US7494979B2 (en) * | 2003-06-13 | 2009-02-24 | Ironwood Pharmaceuticals, Inc. | Method for treating congestive heart failure and other disorders |
WO2007022531A2 (en) * | 2005-08-19 | 2007-02-22 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US20110172126A1 (en) * | 2008-09-03 | 2011-07-14 | Xenome Ltd | Libraries of peptide conjugates and methods for making them |
DK2536742T3 (en) * | 2010-02-17 | 2017-09-04 | Ironwood Pharmaceuticals Inc | TREATMENTS FOR GASTROINTESTINAL DISORDERS |
CA2902348C (en) * | 2013-02-25 | 2021-11-30 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
WO2016015055A1 (en) * | 2014-07-25 | 2016-01-28 | Ironwood Pharmaceuticals, Inc. | Colon cleansing compositions |
-
2016
- 2016-04-29 CA CA3172777A patent/CA3172777A1/en active Pending
- 2016-04-29 CN CN202210288669.XA patent/CN114716514A/zh active Pending
- 2016-04-29 CA CA2984437A patent/CA2984437A1/en active Pending
- 2016-04-29 MD MDE20180232T patent/MD3288578T2/ro unknown
- 2016-04-29 RS RS20230311A patent/RS64160B1/sr unknown
- 2016-04-29 SI SI201631712T patent/SI3288578T1/sl unknown
- 2016-04-29 WO PCT/US2016/030061 patent/WO2016178979A1/en active Application Filing
- 2016-04-29 PL PL16721609.2T patent/PL3288578T3/pl unknown
- 2016-04-29 EA EA201792401A patent/EA201792401A1/ru unknown
- 2016-04-29 CN CN201680032088.2A patent/CN108040482B/zh active Active
- 2016-04-29 HU HUE16721609A patent/HUE061954T2/hu unknown
- 2016-04-29 US US15/570,838 patent/US10618938B2/en active Active
- 2016-04-29 LT LTEPPCT/US2016/030061T patent/LT3288578T/lt unknown
- 2016-04-29 MX MX2017013928A patent/MX2017013928A/es unknown
- 2016-04-29 FI FIEP16721609.2T patent/FI3288578T3/fi active
- 2016-04-29 PT PT167216092T patent/PT3288578T/pt unknown
- 2016-04-29 BR BR112017023539A patent/BR112017023539A2/pt active Search and Examination
- 2016-04-29 JP JP2017557067A patent/JP6930919B2/ja active Active
- 2016-04-29 DK DK16721609.2T patent/DK3288578T3/da active
- 2016-04-29 MA MA41985A patent/MA41985B1/fr unknown
- 2016-04-29 ES ES16721609T patent/ES2947591T3/es active Active
- 2016-04-29 EP EP16721609.2A patent/EP3288578B8/en active Active
- 2016-04-29 EP EP23159398.9A patent/EP4218789A3/en active Pending
- 2016-04-29 KR KR1020177034808A patent/KR20180005675A/ko not_active Application Discontinuation
- 2016-04-29 HR HRP20230381TT patent/HRP20230381T1/hr unknown
-
2017
- 2017-10-30 MX MX2022013283A patent/MX2022013283A/es unknown
-
2020
- 2020-09-30 JP JP2020165328A patent/JP2020203954A/ja not_active Withdrawn
-
2022
- 2022-07-04 JP JP2022107644A patent/JP2022121734A/ja active Pending
-
2023
- 2023-05-26 CY CY20231100253T patent/CY1126031T1/el unknown
- 2023-12-11 JP JP2023208395A patent/JP2024015335A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20230381T1 (hr) | Pripravci za čišćenje debelog crijeva i liječenje gastrointestinalnih poremećaja | |
JP6651546B2 (ja) | カッパ(κ)オピオイド受容体(KOR)アゴニストとしての新規の短鎖ペプチド | |
RU2011138011A (ru) | Миметики аполипопротеина а-i | |
JP2017535527A5 (hr) | ||
AU2018220168A1 (en) | Novel alpha4beta7 peptide dimer antagonists | |
AU2368899A (en) | New peptide compounds that are analogues of the glucagon-like peptide-1 (7-37), a process for their preparation and pharmaceutical compositions containing them | |
RU2017134274A (ru) | Связывающие tslp белки | |
EA201170337A1 (ru) | Стабильная твердая композиция полипептидного агониста gc-c рецептора, приемлемая для перорального введения | |
RU2017146657A (ru) | Пролекарства, содержащие коньюгат гиалуроновой кислоты, ликера и и двойного агониста glp-1глюкагона | |
JP2014524444A5 (hr) | ||
US11965039B2 (en) | Compstatin analogues and their medical uses | |
RU2012109415A (ru) | Способ модуляции фармакодинамического эффекта перорально вводимых агонистов рецептора гуанилатциклазы | |
JP2018519254A5 (hr) | ||
US20150166617A1 (en) | Compositions and methods of treating alzheimer's disease | |
WO2021037942A1 (en) | Compstatin analogues and their medical uses | |
JP2020037570A (ja) | オピオイド誘発性機能障害の治療に有用なグアニル酸シクラーゼのアゴニスト | |
AR088727A1 (es) | Peptidos ciclicos con actividad antineoplasica y antiangiogenica | |
US10632187B2 (en) | Hemagglutinin-binding peptide | |
CN102574904B (zh) | 赋予了经粘膜吸收性的胃动素样肽化合物 | |
Cai et al. | New pseudononapeptide bombesin antagonists with C-terminal leu-psi (ch2n) tac-nh2 show high binding-affinity to bombesin/grp receptors on cfpac-1 human pancreatic-cancer cells | |
Fang et al. | Pharmacological effects of the dansylated neuropeptide FF analogues on body temperature and morphine analgesia | |
JP2002534996A5 (hr) | ||
JPH06511495A (ja) | ニューロメジンb受容体拮抗物質 | |
Mukai et al. | Structure-activity relationships of mammalian bombesin-like neuropeptides in the contraction of rat uterus | |
RU2008129731A (ru) | Новые пептиды-т-хелперные антигенные детерминанты (thd) |